Abstract
Background Multispectral optoacoustic tomography (MSOT), a molecular sensitive ultrasound, offers a non-invasive diagnostic approach to image the deep-tissue biomarkers.
Objectives The authors aimed to investigate the diagnostic accuracy of MSOT to distinguish between healthy volunteers (HV) and patients with intermittent claudication (IC) by assessing hemoglobin-related biomarkers in calf muscle tissue.
Methods In this monocentric, cross-sectional diagnostic trial using derivation (DC) and validation cohorts (VC) yll subjects underwent standardized PAD diagnostics. This included pulse palpation, ankle brachial index (ABI), duplex sonography, 6-minute walk test (6MWT), and assessment of health-related quality of life (VASCUQOL-6). The vascular occlusion profile in IC patients was confirmed by angiography (aggregated TransAtlantic Inter-Society Consensus classification, aTASC). MSOT imaging of calf muscle was performed before and after standardized heel raise provocation.
Participants Of 123 screened individuals, 102 completed the study. MSOT-derived oxygenation (msO2) after the exercise differentiated IC and HV with an area under curve the receiver operator characteristics curve (AUROC) in DC by 0.99 (95%CI 0.97;1.00, p<0.001, sensitivity: 100%, specificity: 95.8%) and in the VC by 0.95 (95%CI 0.95;1.00, p<0.001, sensitivity: 96.2%, specificity: 96.0%). mSO2 positively correlated with the ABI post-exercise (R=0.83, 95%CI 0.75;0.88, P<0.001), the absolute walking distance in the 6MWT (R=0.77, 95%CI 0.68;0.84, P<0.001), the VASCUQOL-6 (R=0.79, 95%CI 0.70;0.85, P<0.001) and negatively with aTASC classification (R=-0.80, 95%CI -0.86;-0.72, P<0.001).
Conclusions Post-exercise MSOT-derived saturation in the calf muscle was validated as a new and promising diagnostic biomarker to distinguish between HV and IC patients yielding high sensitivity and specificity. (NCT05373927)
Competing Interest Statement
A.R., M. W. and F. K. are shared patent holders on a related Optoacoustic system described in the study. All others declare no conflict of interest.
Clinical Trial
NCT05373927
Funding Statement
U.R. received support from the ELAN Fond at the University Hospital of the FAU Erlangen-Nuernberg. A.R. received funding from Interdisciplinary Center for Clinical Research (IZKF), Junior project J089.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the local ethics committee of the University Erlangen-Nuernberg (22-62-Bm).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest
A.R., M. W. and F. K. are shared patent holders on a related Optoacoustic system described in the study. All others declare no conflict of interest.
Tweet
Non-invasive #MSOT imaging provides high diagnostic yield for detecting patients with early peripheral artery disease. @FerdiKnie @PETI_Lab
